caa a22 4500 445797665 CHVBK 20180317145131.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10620-011-1933-2 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1933-2 Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy [Elektronische Daten] [Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David van Thiel, Sabine Mihm, Giuliano Ramadori] Background and Aims: The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200mg and results in response rates of 80%. However, this therapy has substantial side-effects including anemia, is teratogenic, and costly. To reduce the side-effects of therapy, the role of monotherapy consisting of only IFN-α was investigated. Methods: A retrospective analysis of individual therapy courses of HCV-G3-infected patients who were treated with IFN-α2a monotherapy or a combination therapy with attention to the treatment outcome and the presence of IL28B rs12979860 and IL28B rs8099917 single-nucleotide polymorphism genotypes was performed. Conventional prognostic features in each case were assessed as well. Results: In the study, 15/30 (50%) of patients treated with IFN-α2a monotherapy and 32/36 (89%) treated with combination therapy achieved a sustained virological response (SVR). In addition, 7/11 (64%) of those treated initially with monotherapy and subsequently with combination therapy achieved an SVR. An "ultra-rapid” virological response occurring within 2weeks of initiation of therapy (p=0.005), young age (<40; p<0.001) and low initial γ-GT/ALT-ratio (p=0.03) were associated with a SVR to IFN-α2a monotherapy. An SVR in those treated with combination therapy was found to be associated with a rapid virological response (RVR) (p=0.03). The absence of histologic steatosis was associated with SVR in all patient groups (p=0.01). Therapy duration (24 vs. 48weeks) did not affect the SVR in either group. As expected, combination therapy resulted in more hematological side-effects than did monotherapy. Conclusions: An "ultra-rapid” virological response, young age, low initial γ-GT/ALT-ratio and absence of steatosis were each associated with an SVR in those receiving IFN-α2a monotherapy. Therefore, monotherapy in these patients should still be discussed independently of the existence of the IL28B polymorphisms. The Author(s), 2011 Chronic hepatitis C virus infection nationallicence Treatment nationallicence Monotherapy nationallicence Ribavirin nationallicence Amanzada Ahmad Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut Goralczyk Armin General and Visceral Surgery, University Medical Center Göttingen, Göttingen, Germany aut Moriconi Federico Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut Blaschke Martina Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut Schaefer Inga-Marie Department of Pathology, University Medical Center Göttingen, Göttingen, Germany aut van Thiel David Division of Liver Disease, Rush University Medical Center, Chicago, IL, USA aut Mihm Sabine Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut Ramadori Giuliano Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/11(2011-11-01), 3296-3304 0163-2116 56:11<3296 2011 56 10620 https://doi.org/10.1007/s10620-011-1933-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1933-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Amanzada Ahmad Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut NATIONALLICENCE 700 1- Goralczyk Armin General and Visceral Surgery, University Medical Center Göttingen, Göttingen, Germany aut NATIONALLICENCE 700 1- Moriconi Federico Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut NATIONALLICENCE 700 1- Blaschke Martina Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut NATIONALLICENCE 700 1- Schaefer Inga-Marie Department of Pathology, University Medical Center Göttingen, Göttingen, Germany aut NATIONALLICENCE 700 1- van Thiel David Division of Liver Disease, Rush University Medical Center, Chicago, IL, USA aut NATIONALLICENCE 700 1- Mihm Sabine Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut NATIONALLICENCE 700 1- Ramadori Giuliano Department of Gastroenterology and Endocrinology, University Medical Center Göttingen, Georg-August-University, Robert-Koch-Straße 40, 37075, Göttingen, Germany aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/11(2011-11-01), 3296-3304 0163-2116 56:11<3296 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer